Skip to content

Development and Application Verification of LLM Based Stroke Intelligent Health Rivisit Mangage System

Development and Application Verification of LLM Based Stroke Intelligent Health Rivisit Mangage System

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115830
Enrollment
Unknown
Registered
2025-12-31
Start date
2026-01-26
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Intervention group:Rivisit management for stroke patients via stroke intelligent health rivisit mangage system, includes blood pressure monitor, stroke symptom assess, compliance monitor of drug usage
Control group:Ordinary health education after discharge and telephone revisit based on artificial way.

Sponsors

Xuanwu Hospital Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age>=18, male or female; 2.Acute ischaemic stroke patient onsetted within 2 weeks; 3.CT scan or MRI confirmed fulfilled diagnostic criteria within 2 weeks; 4.Local civilian lived 6 months and beyond; 5.patients whom, willing to enter for the trial, high compliance and available to sign for the informed consent; 6.purchase with smart phone or other intelligent devices. Participants could only be included if they followed all criterias at the same time.

Exclusion criteria

Exclusion criteria: 1.Female individuals in gestation or breastfeeding period, or possitive result of pregnancy test before cluster randomization; 2.Patient accepting psychiatric or mental treatment that might pollut the result; 3.Life expectancy less than one year (e.g. complicated with malignant tumour, severe cardiac or pulmonary diseases); 4.Participant in other intervention studies that might interfere the result; 5.Investigators belief that patient is not suitable for this trial, or other situations that might have significant threat to the patient (e.g. cognitive impairment that could not understand and/or obey the programme and/or follow-up). The patient would be excluded if any one of these criteria have been attached.

Design outcomes

Primary

MeasureTime frame
Qualified rate of 90 days' systolic blood pressure;

Secondary

MeasureTime frame
Relapse of stroke in 90 days;Compliance monitor of drug usage;Ability status post disease;Life quality;Knowledgement degree of secondary prevention against risk factor;Other relative index of stroke risk factor;

Countries

China

Contacts

Public ContactZhao Jie

Xuanwu Hospital Capital Medical University

Smilezoe51@163.com+86 186 0124 3661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026